Company news
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news
Every Sarepta Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
July 16, 2025
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
June 15, 2025
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
June 4, 2025
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
May 21, 2025
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
May 16, 2025
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
May 16, 2025
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
May 13, 2025
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
May 8, 2025
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
May 6, 2025
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
April 22, 2025
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
April 15, 2025
Sarepta Therapeutics Provides Update on ELEVIDYS
April 4, 2025
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
February 28, 2025
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
February 26, 2025
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
February 14, 2025
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
February 12, 2025
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
February 10, 2025
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
January 27, 2025
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
January 13, 2025
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
December 18, 2024
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
November 26, 2024
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
November 26, 2024
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
November 6, 2024
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
October 23, 2024
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
September 26, 2024
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
September 16, 2024
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
September 5, 2024
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
August 7, 2024
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
July 29, 2024
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
June 20, 2024
Sarepta Therapeutics Set to Join S&P MidCap 400
May 29, 2024
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
May 3, 2024
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
May 1, 2024
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
April 24, 2024
Sarepta Therapeutics to Present at Upcoming Investor Conferences
March 4, 2024
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
February 29, 2024
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
February 28, 2024
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
February 21, 2024
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
February 16, 2024
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
January 29, 2024
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
January 16, 2024
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
January 8, 2024
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
December 22, 2023
Sarepta Therapeutics to Present at the UBS Biopharma Conference
November 2, 2023
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
November 1, 2023
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
October 30, 2023
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
October 25, 2023